Study of SI000413 in Knee Osteoarthritis Patients

Osteoarthritis, Knee Clinical Trial

Official title:

Eight-week, Multi-centre, Dose-response, Double Blind, Placebo-controlled, Randomized, Parallel-group, PhaseⅡ Trial to Evaluate Efficacy and Safety of SI000413 in Patients With Knee Osteoarthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01525758
• Other study ID #: SI000413_OA_?
• Status: Recruiting
• Phase: Phase 2
• First received: January 31, 2012
• Last updated: August 12, 2013
• Start date: January 2012
• Est. completion date: December 2013

Study information

• Verified date: August 2013
• Source: Dong-A ST Co., Ltd.
• Contact: Yoon-Jae Cho, MD
• Email: yjcho[@]khmc.or.kr
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of SI000413 in patients with knee osteoarthritis by orally administration and to determine optimal dose.

Description:

This is a dose-response, double blind , placebo-controlled study. All patients are required to have 2 weeks washout period from prior medication. Subjects will discontinue current medications 2 weeks prior to randomization. Among those who meet the inclusion criteria, only subjects recording visual analogue scale(VAS) of higher than 40mm(VAS range from 0mm(no pain) to 100mm(unbearable pain)) are enrolled in this study.

Subjects meeting screening criteria will be randomized to receive 8 weeks dosing of an active dose of SI000413 or placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Males and females, 35-75 years old

2. Subjects must have a clinical or radiographic diagnosis of primary OA of the knee (diagnosed according to the ACR)

• The presence of knee pain

• At least one of the following

• age older than 50 years

• morning stiffness lasting less than 30 minutes

• crepitus with motion

3. Subjects must have been symptomatic for at least 3 months prior to enrollment.

4. Subjects must be required to have experienced a pain intensity of at least 40mm on a 100-mm visual analogue scale in the most severely affected joint during the 24 hours prior to randomization.

5. Adequate liver and kidney function

• Adequate liver function : SGOT, SGPT must be within 1.5 x normal limit

• Adequate kidney function : Serum creatinine must be within 1.5 x normal limit

6. Subjects must be able to read, understand and follow the study instructions

7. Subjects must agree to informed consent spontaneously.

Exclusion Criteria:

1. Subjects who are not using adequate birth control.

2. Pregnant or breast-feeding.

3. Subjects requiring Knee surgery within 1 year of screening anticipating any need for a surgical procedure during the study.

4. Secondary OA patients

5. Similar OA patients(ex. rheumatic arthritis, bursitis etc)

6. Treatment with intra-articular injections of systemic corticosteroids or hyaluronic acid in the prior 3 months.

7. Use of drugs or psychotropic medicine(methadone maintenance program, codeine, tramadol hydrochloride)

8. Anemia or coagulant disorder

9. Use of anticoagulants or lithium

10. Use of misoprostol or H2-blocker(including anti ulcer medicine)

11. Presence or history of gastrointestinal bleeding within the past 1 year.

12. Subjects who have serious problem with cardiovascular, respiratory, endocrine, central nervous or History of neurotic mental.

13. Active malignancy of any type(ex. lymphoma, multiple myeloma etc)

14. Use of any medication that will affect pain perception during the study period; physical therapy, corticosteroids, NSAIDs, asprin, topical analgesics.

15. Use of glucosamine, chondroitin during the study period.

16. Change of concomitant dose/use within 4 weeks.

17. Known allergy or hypersensitivity to medicine.

18. Subjects received hormone replacement therapy.

19. Use of any other investigational drug within 1 month prior to screening.

20. Investigators determines that it is not appropriate.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• SI000413
1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
• microcrystalline cellulose
identical number of tablets to active drug groups

Locations

Country	Name	City	State
Korea, Republic of	Ajou University Medical Center	Gyeonggi-do	Woncheon-dong Yeongtong-gu, Suwon
Korea, Republic of	KyungHee University medical center	Seoul	Hoegi-dong, Dongdaemun-gu
Korea, Republic of	Seoul National University Hospital	Seoul	Yongon-dong, Chongno-gu

Sponsors (1)

Lead Sponsor	Collaborator
Dong-A Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	K-WOMAC	The primary endpoint will be the change in the sum of the K-WOMAC OA index at Visit 6(8 weeks) vs. baseline(Visit 2, 0 week).	Visit 6(8 week), baseline	No
Secondary	knee pain intensity assessment	The change from baseline to each day(4 week and 8 week). Subjects assess knee pain intensity by using 100mm VAS at each time.	baseline, Visit 4(4 week), Visit 6(8 week)	No
Secondary	Global assessment(regarding to disease activity)	The change from Visit 4 to Visit 6 using 100mm VAS. Each patient and investigator assess by using 100mm VAS.	Visit 4(4 week), Visit 6(8 week)	No
Secondary	K-WOMAC each domain assessment	The change from Visit 6(8 weeks) vs. baseline(Visit 2, 0 week) in the K-WOMAC each domain score.; * K-WOMAC 3 domains: pain domain, stiffness domain, physical function domain	baseline, Visit 6(8 week)	No
Secondary	ESR & hs-CRP	The change from baseline to each day(Visit 4, Visit 6) using laboratory test.	baseline, Visit 4(4 week), Visit 6(8 week)	No